Press Releases Defence Therapeutics Inc.

Equities

DTC

CA24463V1013

Market Closed - Canadian Securities Exchange Other stock markets 20:59:39 10/05/2024 BST			5-day change	1st Jan Change
1.31 ^CAD	-6.43%		-10.88%	-43.78%

03-26	Defence Therapeutics Inc. Announces the Successful Testing of Second-Generation Anti-Cancer Vaccine, Called ARM-002TM	CI
03-01	Defence Therapeutics Inc. Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE	05-02	EQ
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine	05-01	NE
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation	04-23	NE
DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION	04-23	EQ
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth	04-17	NE
DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH	04-17	EQ
Defence Therapeutics Announces Warrant Terms Amendment	04-05	NE
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION	03-26	EQ
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine	03-26	NE
DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE	03-26	EQ
Defence Completes 2nd Tranche of Financing	03-22	NE
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology	03-04	NE
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY	03-04	EQ
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update	02-29	NE
Defence Therapeutics Completes 1st Tranche of Financing	01-31	NE
Defence Financing	01-20	NE
Defence Begins Trading on the OTCQB and Arranges Financing	01-13	NE
Defence's AccuTOX(R) Impairs Lung Cancer Growth	01-10	NE
DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH	01-10	EQ
Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)	12-12	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Defence Therapeutics Inc.

Equities

DTC

CA24463V1013

Press Releases

Filters